PBA 0405
Alternative Names: PB-004; PB004 PureBIKE; PB004.22.0405.aF; PBA-0405Latest Information Update: 23 Jul 2024
At a glance
- Originator Pure Biologics
- Class Antibodies; Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase 0 Solid tumours
Most Recent Events
- 18 Jul 2024 Pure Biologics and Twist Bioscience Corporation agree for collaboration for use of synthetic antibody phage display libraries
- 29 Apr 2024 Phase-0 for Solid tumours (Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT06273852)
- 18 Jan 2024 Preclinical trials in Solid tumours in Poland (Parenteral) (Pure Biologics Pipeline, January 2024)